Literature DB >> 26293308

Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Katsuyoshi Mizukami1,2, Hiroyasu Akatsu3,4, Eric E Abrahamson5,6, Zhiping Mi5, Milos D Ikonomovic5,7,6.   

Abstract

Studies of acetylcholine degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in Alzheimer's disease (AD) have suggested their potential role in the development of fibrillar amyloid-β (Aβ) plaques (amyloid plaques). A recent genome-wide association study analysis identified a novel association between genetic variations in the BCHE locus and amyloid burden. We studied BChE immunoreactivity in hippocampal tissue sections from AD and control cases, and examined its relationship with amyloid plaques, neurofibrillary tangles (NFT), dystrophic neurites (DN) and neuropil threads (NT). Compared to controls, AD cases had greater BChE immunoreactivity in hippocampal neurons and neuropils in CA2/3, but not in the CA1, CA4 and dentate gyrus. The majority of amyloid plaques (> 80%, using a pan-amyloid marker X-34) contained discrete neuritic clusters which were dual-labeled with antibodies against BChE and phosphorylated tau (clone AT8). There was no association between overall regional BChE immunoreaction intensity and amyloid plaque burden. In contrast to previous reports, BChE was localized in only a fraction (~10%) of classic NFT (positive for X-34). A similar proportion of BChE-immunoreactive pyramidal cells were AT8 immunoreactive. Greater NFT and DN loads were associated with greater BChE immunoreaction intensity in CA2/3, but not in CA1, CA4 and dentate gyrus. Our results demonstrate that in AD hippocampus, BChE accumulates in neurons and plaque-associated neuritic clusters, but only in a small proportion of NFT. The association between greater neurofibrillary pathology burden and markedly increased BChE immunoreactivity, observed selectively in CA2/3 region, could reflect a novel compensatory mechanism. Since CA2/3 is generally considered more resistant to AD pathology, BChE upregulation could impact the cholinergic modulation of glutamate neurotransmission to prevent/reduce neuronal excitotoxicity in AD hippocampus.
© 2015 Japanese Society of Neuropathology.

Entities:  

Keywords:  alzheimer's disease; amyloid; butyrylcholinesterase; hippocampus; tau

Mesh:

Substances:

Year:  2015        PMID: 26293308      PMCID: PMC4761534          DOI: 10.1111/neup.12241

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  37 in total

1.  X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.

Authors:  S D Styren; R L Hamilton; G C Styren; W E Klunk
Journal:  J Histochem Cytochem       Date:  2000-09       Impact factor: 2.479

2.  Acetylcholinesterase fibers and the development of senile plaques.

Authors:  H Tago; P L McGeer; E G McGeer
Journal:  Brain Res       Date:  1987-03-17       Impact factor: 3.252

3.  Evidence for cholinergic neurites in senile plaques.

Authors:  C A Kitt; D L Price; R G Struble; L C Cork; B H Wainer; M W Becher; W C Mobley
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

4.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.

Authors:  M-M Mesulam; A Guillozet; P Shaw; A Levey; E G Duysen; O Lockridge
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 5.  Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.

Authors:  Changiz Geula; Sultan Darvesh
Journal:  Drugs Today (Barc)       Date:  2004-08       Impact factor: 2.245

6.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Changes in brain cholinesterases in senile dementia of Alzheimer type.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Neuropathol Appl Neurobiol       Date:  1978 Jul-Aug       Impact factor: 8.090

9.  Cholinergic innervation in neuritic plaques.

Authors:  R G Struble; L C Cork; P J Whitehouse; D L Price
Journal:  Science       Date:  1982-04-23       Impact factor: 47.728

10.  Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer's disease.

Authors:  E G McGeer; P L McGeer; H Kamo; H Tago; R Harrop
Journal:  Can J Neurol Sci       Date:  1986-11       Impact factor: 2.104

View more
  1 in total

Review 1.  Expression and Function of the Cholinergic System in Immune Cells.

Authors:  Takeshi Fujii; Masato Mashimo; Yasuhiro Moriwaki; Hidemi Misawa; Shiro Ono; Kazuhide Horiguchi; Koichiro Kawashima
Journal:  Front Immunol       Date:  2017-09-06       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.